timothy sykes logo
CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal Thumbnail
G Google News

CELC Stock Jumps As VIKTORIA-1 Trial Hits Key Goal

TIM SYKES•UPDATED MAY. 4, 2026, 5:04 PM ET
Reviewed by Bryce Tuoheyand Fact-checked by Matt Monaco

Celcuity Inc. stocks have been trading up by 15.38 percent after promising clinical trial news boosted investor confidence.

Candlestick Chart

Live Update At 17:03:55 EDT: On Monday, May 04, 2026 Celcuity Inc. stock [NASDAQ: CELC] is trending up by 15.38%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

CELC has been trading like a classic biotech catalyst story. In mid-April, Celcuity Inc. sat around the low-$120s. Over the last few weeks, CELC pushed from roughly $117–$122 up toward the mid-$140s, closing at $144.98 on 2026/05/04 after a strong intraday range between $136.06 and $151.02. That kind of expansion in range usually tells traders that news is driving real price discovery.

Intraday, CELC held most of its morning gap, with steady trading between $144 and $151 and only brief dips being bought. That intraday action shows dip buyers lurking and shorts unable to crack the trend, at least for now. For momentum traders, CELC is behaving like a name in play, not a sleepy biotech.

Fundamentals tell a different, but typical, early-stage story. Celcuity posted a quarterly net loss of about $50.97M and negative operating cash flow of roughly $36.40M. Returns on equity and assets are deeply negative, and the price-to-book near 60 shows traders paying up for pipeline, not current earnings. The flip side: CELC ended the period with $165.7M in cash and a very strong current ratio above 10, giving Celcuity room to fund operations into the next regulatory milestones. For active traders, CELC is all about data, approvals, and sentiment swings, not value metrics.

Why Traders Are Watching CELC Now

CELC has moved to the front of many biotech watchlists because the latest VIKTORIA-1 data changes the story from “promising” to “de-risked.” Celcuity announced that its Phase 3 VIKTORIA-1 trial in PIK3CA-mutant HR+/HER2- metastatic breast cancer met its primary endpoint. Gedatolisib, combined with fulvestrant, with or without palbociclib, delivered statistically significant and clinically meaningful improvements in progression-free survival versus alpelisib plus fulvestrant.

For traders, that matters more than any single-day pop. In late-stage oncology, a successful Phase 3 readout is often the biggest binary event in the whole life of a program. When CELC proved it could beat an established regimen in this genetically defined group, the risk profile on gedatolisib shifted sharply. The market is now treating Celcuity Inc. less like a speculative science project and more like a potential future revenue story.

The topline PIK3CA-mutant data do not stand alone. CELC had already reported positive results from the PIK3CA wild-type cohort in the same VIKTORIA-1 trial. Put together, Celcuity can now argue for broad second-line use of gedatolisib across both mutant and wild-type HR+/HER2- advanced breast cancer. That is a much larger addressable pool than a narrow niche label, and traders know expanded labels can justify premium valuations.

On the regulatory side, CELC plans to file a supplemental NDA using the new PIK3CA-mutant data. Meanwhile, gedatolisib already sits under Priority Review for the wild-type setting with a firm 2026/07/17 PDUFA date. A clear calendar catalyst like that often acts as a magnet for speculative trading as the date approaches. Add in Citizens launching coverage with an Outperform rating and a $150 price target, and you have Wall Street validation layered on top of the science. Expectations are now higher, which can amplify both rallies and pullbacks in CELC.

More Breaking News

Conclusion

CELC is showing traders what a full biotech catalyst cycle looks like: big data, sharp moves, and a crowded tape. Celcuity Inc. has stacked several positives in a short period — successful Phase 3 VIKTORIA-1 data in PIK3CA-mutant patients, previously strong wild-type results, and a defined 2026/07/17 PDUFA date under Priority Review. The planned supplemental NDA based on the new cohort aims to widen gedatolisib’s reach and turn clinical wins into potential commercial reality.

Financially, CELC remains a classic development-stage biotech: heavy R&D spend, negative earnings, but a solid cash cushion and access to capital. The balance sheet shows enough liquidity to push through near-term milestones, but traders in Celcuity Inc. still live and die by headlines, not by dividends or steady cash flows.

For active traders, the playbook is straightforward: CELC is an event-driven name where chart levels and news timing matter as much as spreadsheets. As millionaire penny stock trader and teacher Tim Sykes, says, “Consistency is key in trading; don’t let emotions dictate your trades.”. In the words of Tim Sykes, “Patterns repeat, but only for those who study every detail and cut losses ruthlessly.” Applied to CELC, that means respecting the volatility, tracking every regulatory step on gedatolisib, and treating each surge as an opportunity only if you have a clear trading plan. This article is for educational and research purposes only and is not investment advice.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Click Here for a Millionaire's POV on Trading CELC

Millionaire's
POV on CELC

Don't miss the next
big breakout.

GET POV
Tim Sykes

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”